JP7387630B2 - Smarca2/4分解剤としてのピリダジン誘導体 - Google Patents

Smarca2/4分解剤としてのピリダジン誘導体 Download PDF

Info

Publication number
JP7387630B2
JP7387630B2 JP2020554235A JP2020554235A JP7387630B2 JP 7387630 B2 JP7387630 B2 JP 7387630B2 JP 2020554235 A JP2020554235 A JP 2020554235A JP 2020554235 A JP2020554235 A JP 2020554235A JP 7387630 B2 JP7387630 B2 JP 7387630B2
Authority
JP
Japan
Prior art keywords
cancer
synthesis
compound
amino
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020554235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520372A5 (cg-RX-API-DMAC7.html
JP2021520372A (ja
Inventor
サスマル,サンギータ
サマジダル,スサンタ
ムカルジー,サブヘンドュ
アッビネニ,チャンドラセカール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurigene Oncology Ltd
Original Assignee
Aurigene Discovery Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Ltd filed Critical Aurigene Discovery Technologies Ltd
Publication of JP2021520372A publication Critical patent/JP2021520372A/ja
Publication of JP2021520372A5 publication Critical patent/JP2021520372A5/ja
Application granted granted Critical
Publication of JP7387630B2 publication Critical patent/JP7387630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020554235A 2018-04-26 2019-04-26 Smarca2/4分解剤としてのピリダジン誘導体 Active JP7387630B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841015818 2018-04-26
IN201841015818 2018-04-26
PCT/IB2019/053443 WO2019207538A1 (en) 2018-04-26 2019-04-26 Pyridazine derivatives as smarca2/4 degraders

Publications (3)

Publication Number Publication Date
JP2021520372A JP2021520372A (ja) 2021-08-19
JP2021520372A5 JP2021520372A5 (cg-RX-API-DMAC7.html) 2022-05-09
JP7387630B2 true JP7387630B2 (ja) 2023-11-28

Family

ID=68295093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554235A Active JP7387630B2 (ja) 2018-04-26 2019-04-26 Smarca2/4分解剤としてのピリダジン誘導体

Country Status (7)

Country Link
US (2) US12371426B2 (cg-RX-API-DMAC7.html)
EP (1) EP3784665A4 (cg-RX-API-DMAC7.html)
JP (1) JP7387630B2 (cg-RX-API-DMAC7.html)
CN (1) CN112771038B (cg-RX-API-DMAC7.html)
CA (1) CA3118354A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104495YA (cg-RX-API-DMAC7.html)
WO (1) WO2019207538A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547530A (ja) * 2019-09-12 2022-11-14 オーリジーン ディスカバリー テクノロジーズ リミテッド Smarca2/4デグレーダに対する応答者を同定するための方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
WO2020160192A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160193A2 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN114502543A (zh) * 2019-05-24 2022-05-13 拜欧斯瑞克斯公司 靶向蛋白化合物、其药物组合物及治疗应用
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4054724A4 (en) * 2019-10-28 2023-12-27 C4 Therapeutics, Inc. BIFUNCTIONAL CONNECTIONS
CN114728936A (zh) * 2019-10-29 2022-07-08 豪夫迈·罗氏有限公司 用于治疗癌症的双功能化合物
CN110790746B (zh) * 2019-11-18 2020-10-30 南京恒通医药开发有限公司 一种利用微通道反应器连续化制备泊马度胺的合成工艺
US11679109B2 (en) * 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
CA3167166A1 (en) * 2020-01-10 2021-07-15 Amgen Inc. Smarca2-vhl degraders
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
MX2022009308A (es) 2020-01-29 2022-08-22 Foghorn Therapeutics Inc Compuestos y usos de estos.
WO2021163302A1 (en) * 2020-02-12 2021-08-19 Dana-Farber Cancer Institute, Inc. Compounds, compositions, and methods for protein degradation
JP7508578B2 (ja) * 2020-04-06 2024-07-01 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
TWI918648B (zh) 2020-05-06 2026-03-21 美商新銳思生物製藥股份有限公司 造血前驅細胞激酶之雙官能降解劑及其治療用途
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
MX2023001445A (es) * 2020-08-04 2023-05-08 Aurigene Oncology Ltd Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
WO2022099117A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
US20240024488A1 (en) * 2020-11-20 2024-01-25 Foghorn Therapeutics Inc. Compounds and uses thereof
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
CN117337178A (zh) * 2021-05-10 2024-01-02 福宏治疗公司 化合物及其用途
CR20230518A (es) * 2021-05-10 2024-02-13 Foghorn Therapeutics Inc Compuestos y usos de estos
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
CN115611881B (zh) * 2021-07-13 2024-09-20 复旦大学 一种合成新型vhl配体4-f-vh032的方法
JP2024533990A (ja) 2021-08-09 2024-09-18 ジェネンテック, インコーポレイテッド Brmの調節に使用するためのフェノール誘導体
JP2025506452A (ja) * 2022-02-09 2025-03-11 オーリジーン オンコロジー リミテッド Smarca2及び/又はsmarca4分解剤としての3-置換ピリダジン化合物
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024064316A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024064328A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof
IL325247A (en) 2023-06-14 2026-02-01 Astrazeneca Ab History of 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-8,3-diazabicyclo[3.2.1]octane as a protacs from SMARCA2 joints for cancer treatment
PE20260307A1 (es) 2023-06-14 2026-02-11 Astrazeneca Ab Degradadores de smarca2 y usos de estos
CN121816356A (zh) * 2023-07-28 2026-04-07 甘李药业股份有限公司 一种选择性降解smarca2/4的化合物及其应用
CN118406019B (zh) * 2024-07-02 2024-09-20 苏州源起材料科技有限公司 一种噻唑化合物生物医药砌块的合成方法
CN122070278A (zh) * 2024-09-19 2026-05-19 标新生物医药科技(上海)有限公司 含有芳基取代杂芳基的双功能蛋白降解剂及其应用
WO2026120044A1 (en) 2024-12-04 2026-06-11 Astrazeneca Ab Smarca2 degraders and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
JP2018510851A (ja) 2015-02-25 2018-04-19 ジェネンテック, インコーポレイテッド 治療用ピリダジン化合物およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019249849C1 (en) * 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
CA3150354A1 (en) * 2019-09-12 2021-03-18 Muralidhara Ramachandra METHOD FOR IDENTIFYING RESPONDERS TO SMARCA2/4 DEGRADATION AGENTS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510851A (ja) 2015-02-25 2018-04-19 ジェネンテック, インコーポレイテッド 治療用ピリダジン化合物およびその使用
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547530A (ja) * 2019-09-12 2022-11-14 オーリジーン ディスカバリー テクノロジーズ リミテッド Smarca2/4デグレーダに対する応答者を同定するための方法

Also Published As

Publication number Publication date
WO2019207538A1 (en) 2019-10-31
US12371426B2 (en) 2025-07-29
US20240270734A1 (en) 2024-08-15
CN112771038B (zh) 2024-09-24
CN112771038A (zh) 2021-05-07
EP3784665A1 (en) 2021-03-03
US20210253564A1 (en) 2021-08-19
EP3784665A4 (en) 2022-01-26
JP2021520372A (ja) 2021-08-19
CA3118354A1 (en) 2019-10-31
SG11202104495YA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
CN112771038B (zh) 作为smarca2/4降解剂的哒嗪衍生物
CN112262139B (zh) 作为激酶抑制剂的氨基吡咯并三嗪
CN103842340B (zh) 核转运调节剂及其应用
CN107108581B (zh) 作为强效rock抑制剂的回接苯甲酰胺衍生物
CN105073741B (zh) 作为rock抑制剂的酞嗪酮及异喹啉酮
CN114727991B (zh) 作为Kv1.3钾SHAKER通道阻断剂的芳基亚甲基杂环化合物
CN112424188A (zh) 作为parp7抑制剂的哒嗪酮
JP7483678B2 (ja) Pad4阻害剤としての置換ベンズイミダゾール
JP2025186255A (ja) Kv1.3カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
CA3042710A1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
CA2954976A1 (en) Spirocycloheptanes as inhibitors of rock
JP2018526343A (ja) ヒストン脱アセチル化酵素6阻害剤としての1,3,4−オキサジアゾールスルホンアミド誘導体化合物及びこれを含有する薬剤学的組成物
JP2022533147A (ja) 芳香族アミン類のar及びbetを標的とするタンパク質分解キメラ化合物及び使用
CN116490184A (zh) 用于抑制egfr突变癌症的化合物及其药物用途
CN114728177B (zh) 作为Kv1.3钾Shaker通道阻滞剂的芳基杂二环化合物
EP3183239B1 (en) Indazoles
WO2015125785A1 (ja) 複数置換基を有するピラゾロン誘導体
TW202140499A (zh) 巨環rip2-激酶抑制劑
TW202348225A (zh) Myc家族原癌基因蛋白之調節劑
RU2817356C1 (ru) Соединение для разрушения андрогенового рецептора и его фармацевтическое применение
EP4568946A1 (en) Macrocyclic bcl6 degraders
TW202409011A (zh) 人類呼吸道融合病毒及間質肺病毒抑制劑
KR20220014952A (ko) 안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도
JP2025506452A (ja) Smarca2及び/又はsmarca4分解剤としての3-置換ピリダジン化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231016

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231115

R150 Certificate of patent or registration of utility model

Ref document number: 7387630

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150